Actym
Biotech developing truly disruptive Immuno-oncology platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | $25.5m Valuation: $170m | Series A | |
| Total Funding | 000k | ||
Related Content
Actym Therapeutics is a pioneering biotechnology company focused on developing innovative cancer therapies. The company harnesses genetically modified bacterial vehicles to safely introduce therapeutic payloads that activate the immune response within the tumor microenvironment (TME). This novel drug modality is designed to target and enrich in the TME, delivering potent and synergistic payloads specifically to tumors. Actym Therapeutics primarily serves cancer patients, aiming to overcome the hostile tumor immune microenvironment to bring durable benefits. Operating in the oncology market, the company collaborates with scientists, potential partners, and journalists to advance its mission. Actym's business model revolves around research and development, leveraging scientific talents in molecular and microbiology, cancer immunology, and manufacturing. Revenue is generated through partnerships, grants, and potentially future product sales.
Keywords: cancer therapy, genetically modified bacteria, immune response, tumor microenvironment, oncology, biotechnology, innovative therapies, research and development, molecular biology, cancer immunology.